Hariharan Jayaram
Overview
Explore the profile of Hariharan Jayaram including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
SMOOT libraries and phage-induced directed evolution of Cas9 to engineer reduced off-target activity
Cerchione D, Loveluck K, Tillotson E, Harbinski F, DaSilva J, Kelley C, et al.
PLoS One
. 2020 Apr;
15(4):e0231716.
PMID: 32298334
RNA-guided endonucleases such as Cas9 provide efficient on-target genome editing in cells but may also cleave at off-target loci throughout the genome. Engineered variants of Streptococcus pyogenes Cas9 (SpCas9) have...
2.
Huston N, Tycko J, Tillotson E, Wilson C, Myer V, Jayaram H, et al.
CRISPR J
. 2019 Jun;
2:172-185.
PMID: 31225747
Considerable effort has been devoted to developing a comprehensive understanding of CRISPR nuclease specificity. predictions and multiple genome-wide cellular and biochemical approaches have revealed a basic understanding of the Cas9...
3.
Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G, et al.
Nat Med
. 2019 Jan;
25(2):229-233.
PMID: 30664785
Leber congenital amaurosis type 10 is a severe retinal dystrophy caused by mutations in the CEP290 gene. We developed EDIT-101, a candidate genome-editing therapeutic, to remove the aberrant splice donor...
4.
Wang S, Tsui V, Crawford T, Audia J, Burdick D, Beresini M, et al.
J Med Chem
. 2018 Oct;
61(20):9301-9315.
PMID: 30289257
The biological functions of the dual bromodomains of human transcription-initiation-factor TFIID subunit 1 (TAF1(1,2)) remain unknown, although TAF1 has been identified as a potential target for oncology research. Here, we...
5.
Wilson C, Fennell T, Bothmer A, Maeder M, Reyon D, Cotta-Ramusino C, et al.
Nat Methods
. 2018 Mar;
15(4):236-237.
PMID: 29600989
No abstract available.
6.
Giannoukos G, Ciulla D, Marco E, Abdulkerim H, Barrera L, Bothmer A, et al.
BMC Genomics
. 2018 Mar;
19(1):212.
PMID: 29562890
Background: Understanding the diversity of repair outcomes after introducing a genomic cut is essential for realizing the therapeutic potential of genomic editing technologies. Targeted PCR amplification combined with Next Generation...
7.
Bronner S, Murray J, Romero F, Lai K, Tsui V, Cyr P, et al.
J Med Chem
. 2017 Nov;
60(24):10151-10171.
PMID: 29155580
The epigenetic regulator CBP/P300 presents a novel therapeutic target for oncology. Previously, we disclosed the development of potent and selective CBP bromodomain inhibitors by first identifying pharmacophores that bind the...
8.
Crawford T, Audia J, Bellon S, Burdick D, Bommi-Reddy A, Cote A, et al.
ACS Med Chem Lett
. 2017 Jul;
8(7):737-741.
PMID: 28740608
The biological function of bromodomains, epigenetic readers of acetylated lysine residues, remains largely unknown. Herein we report our efforts to discover a potent and selective inhibitor of the bromodomain of...
9.
Bothmer A, Phadke T, Barrera L, Margulies C, Lee C, Buquicchio F, et al.
Nat Commun
. 2017 Jan;
8:13905.
PMID: 28067217
The CRISPR-Cas9 system provides a versatile toolkit for genome engineering that can introduce various DNA lesions at specific genomic locations. However, a better understanding of the nature of these lesions...
10.
Crawford T, Romero F, Lai K, Tsui V, Taylor A, De Leon Boenig G, et al.
J Med Chem
. 2016 Sep;
59(23):10549-10563.
PMID: 27682507
The single bromodomain of the closely related transcriptional regulators CBP/EP300 is a target of much recent interest in cancer and immune system regulation. A co-crystal structure of a ligand-efficient screening...